drugset / Trial / NCT01402076

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

NCT01402076

Phase 1 Completed 24 enrolled Vanda Pharmaceuticals
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this research study is to understand whether there is any difference in the amount of midazolam (including its breakdown product) in the blood when midazolam is given with tasimelteon, and whether there is any difference in the amount of rosiglitazone in the blood when rosiglitazone is given with tasimelteon.

Timeline

Start
2011-08
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 10 mg
Subject Rosiglitazone Small molecule 4 mg
Subject tasimelteon Small molecule 20 mg

Indications

No indication recorded.